Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for December 16, 2009 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Curavisc : successful study regarding the treatment of chronic facet syndrome
A new study was presented at the 4th Annual Congress of the German Spine Society in Munich - it demonstrated the long-term effect of Curavisc in the treatment of chronic facet syndrome 
x-small text small text medium text large text


    KLEINOSTHEIM, GERMANY, December 16, 2009 /24-7PressRelease/ -- It has now been proven that the use of curasan AG's hyaluronic acid preparation Curavisc is safe and sustainably effective also for the treatment of chronic facet syndrome.

Facet syndrome is a chronic pain syndrome caused by an irritation of the joint capsules, mainly in the lumbar spine. It manifests itself as persistent pain that is often difficult to treat. Reasons for the irritation include chronic strain, osteoarthritis or intervertebral disc degeneration.

At the 4th Annual Congress of the German Spine Society, held in Munich from 10th until 12th December, Dr. Hermann Keller presented the open, monocentric study that was carried out at the Spinal and Intervertebral Disc Centre at the Grünewald Clinic in Aschaffenburg, Germany.

A total of 60 patients aged between 40 and 89 had their most badly affected spinal segment, as well as the facet joints located directly above and below, denervated using a highly concentrated glucose solution and were then treated three times at weekly intervals with the hyaluronic acid preparation Curavisc mini. All the patients were systematically treated in advance with anti-inflammatory drugs, 35 of them received accompanying physiotherapy and none of them got an NSAID.

The clinical evaluation in each case was carried out after the final injection using a 6-point scoring system. 24 patients (41%) reported being free of symptoms and 27 (46%) reported a significant improvement.

The individual pain status was assessed on the basis of visual analogue scales (VAS). The symptoms of pain and discomfort decreased continuously for all criteria as the three-week course of treatment progressed; pain at rest by 77%, pain on initial movement by 79% and pain during movement by 78%.

Dr. Hermann Keller was impressed by the positive clinical results: "Already during the period of treatment, it was possible to achieve success for most of the patients. Particularly noteworthy is the fact that improvements for many patients did not just retain after the treatment had ceased, but continued to increase throughout the follow-up phase."

The HA product Curavisc mini for intra-articular treatment is easy to use and was tolerated extremely well. None of the 60 patients had complaints during or after the treatment that could be traced back to the injections.

Conclusion of the study: the injection-based treatment with the hyaluronic acid preparation Curavisc mini appears to be an alternative treatment for chronic facet syndrome, well accepted by the patients.


Press Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
http://www.curasan.de

fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Bianka Wolf:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Bianka Wolf
fr financial relations gmbh

junior consultant
Gutleutstr 75
Frankfurt am Main, Hesse
Germany 60329
Voice: 0049/6995908315
Fax: 0049/6995908399
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.